{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.10","upperLimit":"11.27","value":"8.08"},{"groupId":"OG001","lowerLimit":"5.78","upperLimit":"7.59","value":"6.60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"This measure looks at how long participants with PD-L1 positive tumors (meaning their tumor cells have at least 1% PD-L1, as determined by a lab test called immunohistochemistry or IHC) live without their cancer getting worse after being assigned to a treatment group in the sub-study.\n\nProgression-Free Survival (PFS) is the time from when a participant is assigned to a group (randomization) until their cancer is first shown to get worse (progress), based on reviews by independent experts who do not know which treatment was given. These experts use standard rules (RECIST 1.1) to decide if the cancer has progressed. If a participant dies before their cancer is shown to get worse, the date of death will be used as the time their disease progressed. If a participant's cancer does not get worse and they do not die during the study, their PFS will be measured up to the date of their last tumor check.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Nivolumab 360 mg in combination with Standard of Care treatment every 3 weeks (Q3W) for up to 6 cycles followed by Nivolumab monotherapy 480 mg every 4 weeks (Q4W) - Sub-study","id":"OG000","title":"Treatment 3"},{"description":"Participants received Standard of Care treatment every three weeks (Q3W) for up to 6 cycles - Sub-study","id":"OG001","title":"Treatment 4"}],"paramType":"MEDIAN","populationDescription":"All PD-L1 \\>= 1% Randomized Participants - Sub-study","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)","title":"Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] by Programmed Death-Ligand 1 (PD-L1) Expression at ≥1% Expression by Immunohistochemistry (IHC) for Sub-study","type":"SECONDARY","unitOfMeasure":"Months"}